Pricing Log in Create free account

BioCryst Pharmaceuticals, Inc. (BCRX) vs Regencell Bioscience Holdings Limited (RGC)

BioCryst Pharmaceuticals, Inc. and Regencell Bioscience Holdings Limited are both Drug Manufacturers Specialty & Generic companies. Regencell Bioscience Holdings Limited is the larger, with a market value of $2.6B against $2.0B — 1.3× the size. Regencell Bioscience Holdings Limited has the higher net margin (0.00% vs −37.4%) and the higher return on invested capital (0.00% vs 0.00%). Across the 9 metrics below, BioCryst Pharmaceuticals, Inc. leads on 6 and Regencell Bioscience Holdings Limited on 3.

Valuation

Metric BCRX RGC Drug Manufacturers Specialty & Generic median
P/E n/m n/m 20.55
P/S 2.01 — 2.08
P/B n/m n/m 1.79
Price to free cash flow 5.27 n/m 16.29
EV/EBITDA n/m 1.13 12.22
EV/Sales 2.51 n/m 2.87
Earnings yield (17.88%) (19.96%) (15.94%)
Free cash flow yield 18.98% 0.00% 0.00%

Profitability

Metric BCRX RGC Drug Manufacturers Specialty & Generic median
Gross margin 97.89% — 53.51%
Operating margin (30.10%) — 0.00%
Net margin (37.41%) 0.00% (2.45%)
Free cash flow margin 38.11% 0.00% 0.00%
Return on equity 91.60% 0.00% (0.80%)
Return on assets (69.33%) 0.00% (1.67%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric BCRX RGC Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) 60.30% — 5.22%
EPS growth (last fiscal year) 381.40% (177.78%) 42.91%
Revenue growth, 5-year CAGR 117.89% — 7.24%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric BCRX RGC Drug Manufacturers Specialty & Generic median
Debt to equity 0.00 0.00 0.04
Current ratio 2.71 10.77 2.41
Net debt to EBITDA 0.61 1.22 1.01

Dividend

Metric BCRX RGC Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.45%
Payout ratio — — 0.27

Size

Metric BCRX RGC Drug Manufacturers Specialty & Generic median
Market cap 1.95b 2.61b 315.39m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack